Novavax reports Q2 revenue and updates 2026 guidance
Novavax reported $57M revenue and upwardly revised its 2026 revenue guidance driven by potential earnings from a Sanofi combination trial and existing collaborations. Sentiment reflects a shift toward positive operational visibility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day